Search This Blog

Monday, April 13, 2026

Revolution Medicines' Phase 3 in metastatic pancreatic cancer meets primary, key secondary endpoints

 

Revolution Medicines' Phase 3 RASolute 302 trial of daraxonrasib in metastatic pancreatic cancer meets all primary and key secondary endpoints with significant OS benefit

  • Company plans to include RASolute 302 data in global regulatory filings, including a future FDA New Drug Application.
Posted by at

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.

Subscribe to: Post Comments (Atom)